Related references
Note: Only part of the references are listed.Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years
Kevin L. Winthrop et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Tofacitinib and risk of cardiovascular outcomes: results from the Safety of TofAcitinib in Routine care patients with Rheumatoid Arthritis (STAR-RA) study
Farzin Khosrow-Khavar et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis
Steven R. Ytterberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3B/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS
C. Charles-Schoeman et al.
ANNALS OF THE RHEUMATIC DISEASES (2022)
Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden
Viktor Molander et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Risk of Venous Thromboembolism Associated With Methotrexate Versus Hydroxychloroquine for Rheumatoid Arthritis: A Propensity Score-Matched Cohort Study
Mengdong He et al.
SEMINARS IN ARTHRITIS AND RHEUMATISM (2021)
2021 EULAR recommendations for the implementation of self-management strategies in patients with inflammatory arthritis
Elena Nikiphorou et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement
Peter Nash et al.
ANNALS OF THE RHEUMATIC DISEASES (2021)
Selectivity of Janus Kinase Inhibitors in Rheumatoid Arthritis and Other Immune-Mediated Inflammatory Diseases: Is Expectation the Root of All Headache?
Masayoshi Harigai et al.
DRUGS (2020)
Risk for Serious Infection With Low-Dose Glucocorticoids in Patients With Rheumatoid Arthritis A Cohort Study
Michael D. George et al.
ANNALS OF INTERNAL MEDICINE (2020)
How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers
Katerina Chatzidionysiou et al.
RMD OPEN (2020)
Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme
Stanley B. Cohen et al.
RMD OPEN (2020)
Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment
Josef S. Smolen et al.
JOURNAL OF RHEUMATOLOGY (2019)
Sex differences in risk factors for myocardial infarction: cohort study of UK Biobank participants
Elizabeth R. C. Millett et al.
BMJ-BRITISH MEDICAL JOURNAL (2018)
Laboratory-based and office-based risk scores and charts to predict 10-year risk of cardiovascular disease in 182 countries: a pooled analysis of prospective cohorts and health surveys
Peter Ueda et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Disease Activity in Rheumatoid Arthritis and the Risk of Cardiovascular Events
D. H. Solomon et al.
ARTHRITIS & RHEUMATOLOGY (2015)
Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT
Anja Strangfeld et al.
ARTHRITIS RESEARCH & THERAPY (2010)